Literature DB >> 10913401

Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae.

D Leppert1, S L Leib, C Grygar, K M Miller, U B Schaad, G A Holländer.   

Abstract

To evaluate the spectrum and regulation of matrix metalloproteinases (MMPs) in bacterial meningitis (BM), concentrations of MMP-2, MMP-3, MMP-8, and MMP-9 and endogenous inhibitors of metalloproteinases (TIMP-1 and TIMP-2) were measured in the cerebrospinal fluid (CSF) of 27 children with BM. MMP-8 and MMP-9 were detected in 91% and 97%, respectively, of CSF specimens from patients but were not detected in control patients. CSF levels of MMP-9 were higher (P<.05) in 5 patients who developed hearing impairment or secondary epilepsy than in those who recovered without neurological deficits. Levels of MMP-9 correlated with concentrations of TIMP-1 (P<.001) and tumor necrosis factor-alpha (P=.03). Repeated lumbar punctures showed that levels of MMP-8 and MMP-9 were regulated independently and did not correlate with the CSF cell count. Therefore, MMPs may derive not only from granulocytes infiltrating the CSF space but also from parenchymal cells of the meninges and brain. High concentrations of MMP-9 are a risk factor for the development of postmeningitidal neurological sequelae.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913401     DOI: 10.1086/313922

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  85 in total

Review 1.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 2.  Management of intracranial pressure in tuberculous meningitis.

Authors:  J M K Murthy
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  The paradox of matrix metalloproteinases in infectious disease.

Authors:  P T G Elkington; C M O'Kane; J S Friedland
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

4.  Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis.

Authors:  Damian N Meli; Roney S Coimbra; Dominik G Erhart; Gerard Loquet; Caroline L Bellac; Martin G Täuber; Ulf Neumann; Stephen L Leib
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 5.  Chemotactic factors in cerebrospinal fluid during bacterial meningitis.

Authors:  Petra J G Zwijnenburg; Tom van der Poll; John J Roord; A Marceline van Furth
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

6.  Changes in MMP-9 and TIMP-1 Concentrations in Cerebrospinal Fluid after 1 Week of Treatment of Childhood Bacterial Meningitis.

Authors:  Irmeli Roine; Tuula Pelkonen; Anneli Lauhio; Maija Lappalainen; Manuel Leite Cruzeiro; Luis Bernardino; Taina Tervahartiala; Timo Sorsa; Heikki Peltola
Journal:  J Clin Microbiol       Date:  2015-04-22       Impact factor: 5.948

7.  Association of matrix metalloproteinase-9 in eosinophilic meningitis of BALB/c mice caused by Angiostrongylus cantonensis.

Authors:  H H Lee; H L Chou; K M Chen; S C Lai
Journal:  Parasitol Res       Date:  2004-09-21       Impact factor: 2.289

8.  Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury.

Authors:  Mark Grossetete; Jeremy Phelps; Leopold Arko; Howard Yonas; Gary A Rosenberg
Journal:  Neurosurgery       Date:  2009-10       Impact factor: 4.654

9.  Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels.

Authors:  Reinhilde Mlekusch; Christian Humpel
Journal:  Neurosci Lett       Date:  2009-09-26       Impact factor: 3.046

10.  Could proteomic research deliver the next generation of treatments for pneumococcal meningitis?

Authors:  U R Goonetilleke; S A Ward; S B Gordon
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.